Biovitrum Interim Report January 1 - March 31, 2008
New Strategic Focus. Further Progress in the R&D Portfolio. January - March • Net revenues amounted to SEK 244.3 M (352.9). The profit forthe quarter was SEK -2.1 M (44.1), which represents earnings pershare of SEK -0.05 (0.97). In the first quarter of 2007 Biovitrumdelivered validation batches of ReFacto®, which, in addition tonormal revenues, generated a one-off revenue of SEK 93 M, whichconsiderably affects the comparison between the first quarter 2008vs. the same period 2007. • Cash flow from operations was SEK -22.9 M (48.1). Cash and cashequivalents and short-term